Selective modulators of mutant lrrk2 proteolysis and associated methods of use
AssigneeArvinas Operations, Inc.
InventorsErika Araujo, Michael Berlin, Steven M. Sparks, Jing Wang, Wei Zhang
Life of this patent
Estimating the term…
Loading patent…
AssigneeArvinas Operations, Inc.
InventorsErika Araujo, Michael Berlin, Steven M. Sparks, Jing Wang, Wei Zhang
Estimating the term…
Bifunctional compounds, which find utility as modulators of non-receptor Leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
A hetero-bifunctional compound having the chemical structure:
A method of treating or preventing a disease, a disorder, or symptom associated with LRRK2 comprising, providing a patient in need thereof, and administering an effective amount of a compound as described herein or composition comprising the same to the patient, wherein the compound or composition is effective in treating or ameliorating the disease, disorder, or at least one symptom of the disease or disorder.
Dependencies are inferred from the claim text.